

Altered adenosine-to-inosine RNA editing in human cancer

Genome Research

17, 1586-1595

DOI: [10.1101/gr.6493107](https://doi.org/10.1101/gr.6493107)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Altered editing in cyclic nucleotide phosphodiesterase 8A1 gene transcripts of systemic lupus erythematosus T lymphocytes. <i>Immunology</i> , 2008, 125, 408-419.	2.0	23
2	Epigenetic principles and mechanisms underlying nervous system functions in health and disease. <i>Progress in Neurobiology</i> , 2008, 86, 305-341.	2.8	252
3	Retrotransposons Revisited: The Restraint and Rehabilitation of Parasites. <i>Cell</i> , 2008, 135, 23-35.	13.5	555
4	RNA modifications and human disease. <i>Paediatrics and Child Health (United Kingdom)</i> , 2008, 18, S2-S4.	0.2	0
5	Down-regulation of RNA Editing in Pediatric Astrocytomas. <i>Journal of Biological Chemistry</i> , 2008, 283, 7251-7260.	1.6	172
6	A-to-I RNA editing and cancer: From pathology to basic science. <i>RNA Biology</i> , 2008, 5, 135-139.	1.5	51
7	Gene regulation by SINES and inosines: biological consequences of A-to-I editing of Alu element inverted repeats. <i>Cell Cycle</i> , 2008, 7, 3294-3301.	1.3	85
8	Transcript- and tissue-specific imprinting of a tumour suppressor gene. <i>Human Molecular Genetics</i> , 2009, 18, 118-127.	1.4	54
9	Genomics screen in transformed stem cells reveals RNASEH2A, PPAP2C, and ADARB1 as putative anticancer drug targets. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 249-260.	1.9	64
10	Widespread cleavage of A-to-I hyperediting substrates. <i>Rna</i> , 2009, 15, 1632-1639.	1.6	41
11	Evidence for large diversity in the human transcriptome created by Alu RNA editing. <i>Nucleic Acids Research</i> , 2009, 37, 6905-6915.	6.5	58
12	Inv<i>Alu</i>able junk: The cellular impact and function of Alu and B2 RNAs. <i>IUBMB Life</i> , 2009, 61, 831-837.	1.5	46
13	RNA regulation of epigenetic processes. <i>BioEssays</i> , 2009, 31, 51-59.	1.2	333
14	Editing independent effects of ADARs on the miRNA/siRNA pathways. <i>EMBO Journal</i> , 2009, 28, 3145-3156.	3.5	161
15	RNA editing in human cancer: review. <i>Apmis</i> , 2009, 117, 551-557.	0.9	9
16	Therapeutic MicroRNA Strategies in Human Cancer. <i>AAPS Journal</i> , 2009, 11, 747-57.	2.2	153
17	Dynamic regulation of RNA editing of ion channels and receptors in the mammalian nervous system. <i>Molecular Brain</i> , 2009, 2, 13.	1.3	25
18	The transcript repeat element: the human Alu sequence as a component of gene networks influencing cancer. <i>Functional and Integrative Genomics</i> , 2010, 10, 307-319.	1.4	28

#	ARTICLE	IF	CITATIONS
19	Age-related gene-specific changes of A-to-I mRNA editing in the human brain. <i>Mechanisms of Ageing and Development</i> , 2010, 131, 445-447.	2.2	40
20	All you need to know about retroelements in cancer. <i>Seminars in Cancer Biology</i> , 2010, 20, 200-210.	4.3	166
21	Molecular diversity through RNA editing: a balancing act. <i>Trends in Genetics</i> , 2010, 26, 221-230.	2.9	165
22	Large-scale analysis of structural, sequence and thermodynamic characteristics of A-to-I RNA editing sites in human Alu repeats. <i>BMC Genomics</i> , 2010, 11, 453.	1.2	38
23	Consistent levels of A-to-I RNA editing across individuals in coding sequences and non-conserved Alu repeats. <i>BMC Genomics</i> , 2010, 11, 608.	1.2	33
24	Human <i>BLCAP</i> transcript: new editing events in normal and cancerous tissues. <i>International Journal of Cancer</i> , 2010, 127, 127-137.	2.3	56
25	RNA as the substrate for epigenome-environment interactions. <i>BioEssays</i> , 2010, 32, 548-552.	1.2	64
27	Biochemical polymorphism of the growth hormone system proteins and its manifestations in human prostate cells. <i>Biochemistry (Moscow)</i> , 2010, 75, 1547-1562.	0.7	0
28	Inosine cyanoethylation identifies A-to-I RNA editing sites in the human transcriptome. <i>Nature Chemical Biology</i> , 2010, 6, 733-740.	3.9	163
29	Alu Sequences in Undifferentiated Human Embryonic Stem Cells Display High Levels of A-to-I RNA Editing. <i>PLoS ONE</i> , 2010, 5, e11173.	1.1	72
30	Adenosine-to-inosine RNA editing shapes transcriptome diversity in primates. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 12174-12179.	3.3	155
31	Bladder Cancer-associated Protein, a Potential Prognostic Biomarker in Human Bladder Cancer. <i>Molecular and Cellular Proteomics</i> , 2010, 9, 161-177.	2.5	45
32	Functions and Regulation of RNA Editing by ADAR Deaminases. <i>Annual Review of Biochemistry</i> , 2010, 79, 321-349.	5.0	1,028
33	Possible Editing of Alu Transcripts in Blood Cells of Sporadic Creutzfeldt-Jakob Disease (sCJD). <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 2011, 74, 88-95.	1.1	3
34	Abnormal expression of ADAR1 isoforms in Chinese pediatric acute leukemias. <i>Biochemical and Biophysical Research Communications</i> , 2011, 406, 245-251.	1.0	22
35	Epigenetics, Nervous System Tumors, and Cancer Stem Cells. <i>Cancers</i> , 2011, 3, 3525-3556.	1.7	6
36	Does RNA editing play a role in the development of urinary bladder cancer?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011, 29, 21-26.	0.8	17
37	RNA Editing by Mammalian ADARs. <i>Advances in Genetics</i> , 2011, 73, 87-120.	0.8	99

#	ARTICLE	IF	CITATIONS
38	Multiple Roles of Alu-Related Noncoding RNAs. <i>Progress in Molecular and Subcellular Biology</i> , 2011, 51, 119-146.	0.9	30
39	A-to-I RNA Editing is Induced Upon Hypoxia. <i>Shock</i> , 2011, 35, 585-589.	1.0	31
40	Elucidating the inosinome: global approaches to adenosine-to-inosine RNA editing. <i>Nature Reviews Genetics</i> , 2011, 12, 81-85.	7.7	79
41	Adenosine-to-inosine RNA editing meets cancer. <i>Carcinogenesis</i> , 2011, 32, 1569-1577.	1.3	97
42	Increased RNA editing in children with cyanotic congenital heart disease. <i>Intensive Care Medicine</i> , 2011, 37, 1664-1671.	3.9	32
43	Association between single nucleotide polymorphism-genotype and outcome of patients with chronic lymphocytic leukemia in a randomized chemotherapy trial. <i>Haematologica</i> , 2011, 96, 1496-1503.	1.7	20
44	Bioinformatic Approaches for Identification of A-to-I Editing Sites. <i>Current Topics in Microbiology and Immunology</i> , 2011, 353, 145-162.	0.7	10
45	ADAR2 editing enzyme is a novel human immunodeficiency virus-1 proviral factor. <i>Journal of General Virology</i> , 2011, 92, 1228-1232.	1.3	36
46	Human single-nucleotide polymorphisms alter p53 sequence-specific binding at gene regulatory elements. <i>Nucleic Acids Research</i> , 2011, 39, 178-189.	6.5	28
48	Nuclear Editing of mRNA 3' UTRs. <i>Current Topics in Microbiology and Immunology</i> , 2011, 353, 111-121.	0.7	11
49	Identification of Widespread Ultra-Edited Human RNAs. <i>PLoS Genetics</i> , 2011, 7, e1002317.	1.5	79
50	Darned in 2013: inclusion of model organisms and linking with Wikipedia. <i>Nucleic Acids Research</i> , 2012, 41, D258-D261.	6.5	94
51	Nucleoside analog studies indicate mechanistic differences between RNA-editing adenosine deaminases. <i>Nucleic Acids Research</i> , 2012, 40, 9825-9835.	6.5	23
52	Accurate identification of A-to-I RNA editing in human by transcriptome sequencing. <i>Genome Research</i> , 2012, 22, 142-150.	2.4	297
53	RNA editing in the human ENCODE RNA-seq data. <i>Genome Research</i> , 2012, 22, 1626-1633.	2.4	139
54	A Novel Computational Strategy to Identify A-to-I RNA Editing Sites by RNA-Seq Data: De Novo Detection in Human Spinal Cord Tissue. <i>PLoS ONE</i> , 2012, 7, e44184.	1.1	19
55	Micro-editing mistake translates into a devastating brain tumor. <i>Journal of Clinical Investigation</i> , 2012, 122, 3842-3845.	3.9	7
56	Epigenetics-related genes in prostate cancer: expression profile in prostate cancer tissues, androgen-sensitive and -insensitive cell lines. <i>International Journal of Molecular Medicine</i> , 2012, 31, 21-5.	1.8	24

#	ARTICLE	IF	CITATIONS
57	Systematic identification of edited microRNAs in the human brain. <i>Genome Research</i> , 2012, 22, 1533-1540.	2.4	163
58	Sequence-Dependent Structural Dynamics of Primate Adenosine-to-Inosine Editing Substrates. <i>ChemBioChem</i> , 2012, 13, 2714-2721.	1.3	1
59	A-to-I RNA editing: The "ADAR" side of human cancer. <i>Seminars in Cell and Developmental Biology</i> , 2012, 23, 244-250.	2.3	95
60	A-to-I editing of microRNAs: Regulating the regulators?. <i>Seminars in Cell and Developmental Biology</i> , 2012, 23, 251-257.	2.3	17
61	A Comparative Analysis to Study Editing of Small Noncoding BC200- and Alu Transcripts in Brain of Prion-Inoculated Rhesus Monkeys (<i>M. Mulatta</i>). <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 2012, 75, 391-401.	1.1	2
62	SNP-based large-scale identification of allele-specific gene expression in human B cells. <i>Gene</i> , 2012, 493, 211-218.	1.0	15
63	Increased frequency of single base substitutions in a population of transcripts expressed in cancer cells. <i>BMC Cancer</i> , 2012, 12, 509.	1.1	0
64	Driving transcriptional regulators in melanoma metastasis. <i>Cancer and Metastasis Reviews</i> , 2012, 31, 621-632.	2.7	38
65	Altered A-to-I RNA Editing in Human Embryogenesis. <i>PLoS ONE</i> , 2012, 7, e41576.	1.1	50
66	Identification of Novel Deregulated RNA Metabolism-Related Genes in Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2012, 7, e42086.	1.1	48
67	Transcript Diversification in the Nervous System: A to I RNA Editing in CNS Function and Disease Development. <i>Frontiers in Neuroscience</i> , 2012, 6, 99.	1.4	67
68	Biological Significance of RNA Editing in Cells. <i>Molecular Biotechnology</i> , 2012, 52, 91-100.	1.3	48
69	ADARs: allies or enemies? The importance of A-to-I RNA editing in human disease: from cancer to HIV-1. <i>Biological Reviews</i> , 2012, 87, 95-110.	4.7	65
70	Dicer-microRNA pathway is critical for peripheral nerve regeneration and functional recovery in vivo and regenerative axonogenesis in vitro. <i>Experimental Neurology</i> , 2012, 233, 555-565.	2.0	71
71	Prion infected rhesus monkeys to study differential transcription of Alu DNA elements and editing of Alu transcripts in neuronal cells and blood cells. <i>Journal of Medical Primatology</i> , 2012, 41, 176-182.	0.3	4
72	ADAR2 editing activity in newly diagnosed versus relapsed pediatric high-grade astrocytomas. <i>BMC Cancer</i> , 2013, 13, 255.	1.1	19
73	Hepatocellular carcinoma: Transcriptome diversity regulated by RNA editing. <i>International Journal of Biochemistry and Cell Biology</i> , 2013, 45, 1843-1848.	1.2	17
74	Whole transcriptome RNA-Seq allelic expression in human brain. <i>BMC Genomics</i> , 2013, 14, 571.	1.2	55

#	ARTICLE	IF	CITATIONS
75	A-to-I RNA editing does not change with age in the healthy male rat brain. <i>Biogerontology</i> , 2013, 14, 395-400.	2.0	15
76	RNA editing enters the limelight in cancer. <i>Nature Medicine</i> , 2013, 19, 130-131.	15.2	14
77	Adenosine-to-inosine RNA editing and human disease. <i>Genome Medicine</i> , 2013, 5, 105.	3.6	224
78	Reduction of RNA A-to-I editing in <i>Drosophila</i> acclimated to heat shock. <i>Kaohsiung Journal of Medical Sciences</i> , 2013, 29, 478-483.	0.8	10
79	Mediator Complex Dependent Regulation of Cardiac Development and Disease. <i>Genomics, Proteomics and Bioinformatics</i> , 2013, 11, 151-157.	3.0	14
81	Polymerization of non-complementary RNA: Systematic symmetric nucleotide exchanges mainly involving uracil produce mitochondrial RNA transcripts coding for cryptic overlapping genes. <i>BioSystems</i> , 2013, 111, 156-174.	0.9	40
82	Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma. <i>Nature Medicine</i> , 2013, 19, 209-216.	15.2	421
83	Insulin-like growth factor-binding protein-7 (IGFBP7) transcript: A-to-I editing events in normal and cancerous human keratinocytes. <i>Archives of Dermatological Research</i> , 2013, 305, 519-528.	1.1	10
86	A method to identify RNA A-to-I editing targets using I-specific cleavage and exon array analysis. <i>Molecular and Cellular Probes</i> , 2013, 27, 38-45.	0.9	7
87	Analysis and design of RNA sequencing experiments for identifying RNA editing and other single-nucleotide variants. <i>Rna</i> , 2013, 19, 725-732.	1.6	60
88	The majority of endogenous microRNA targets within Alu elements avoid the microRNA machinery. <i>Bioinformatics</i> , 2013, 29, 894-902.	1.8	30
89	Deletion of the RNA editing enzyme ADAR1 causes regression of established chronic myelogenous leukemia in mice. <i>International Journal of Cancer</i> , 2013, 132, 1741-1750.	2.3	32
91	ADAR2-editing activity inhibits glioblastoma growth through the modulation of the CDC14B/Skp2/p21/p27 axis. <i>Oncogene</i> , 2013, 32, 998-1009.	2.6	122
92	ADAR1 regulates <i>ARHGAP26</i> gene expression through RNA editing by disrupting miR-30b-3p and miR-573 binding. <i>Rna</i> , 2013, 19, 1525-1536.	1.6	79
93	RNA editing of the GLI1 transcription factor modulates the output of Hedgehog signaling. <i>RNA Biology</i> , 2013, 10, 321-333.	1.5	73
94	Global regulation of alternative splicing by adenosine deaminase acting on RNA (ADAR). <i>Rna</i> , 2013, 19, 591-604.	1.6	125
95	RNA Editing and Drug Discovery for Cancer Therapy. <i>Scientific World Journal</i> , The, 2013, 2013, 1-5.	0.8	7
96	Is There an Infectious Agent Behind Prostate Cancer?. , 0, , .		0

#	ARTICLE	IF	CITATIONS
97	RNA editing in <i>RHOQ</i> promotes invasion potential in colorectal cancer. <i>Journal of Experimental Medicine</i> , 2014, 211, 613-621.	4.2	97
98	Inosine in DNA and RNA. <i>Current Opinion in Genetics and Development</i> , 2014, 26, 116-123.	1.5	117
99	ADAR1: a promising new biomarker for esophageal squamous cell carcinoma?. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 865-868.	1.1	13
100	Differential regulation of aggressive features in melanoma cells by members of the miR-17-92 complex. <i>Open Biology</i> , 2014, 4, 140030.	1.5	11
101	Adenosine-to-Inosine RNA Editing Mediated by ADARs in Esophageal Squamous Cell Carcinoma. <i>Cancer Research</i> , 2014, 74, 840-851.	0.4	152
102	A disrupted RNA editing balance mediated by ADARs (Adenosine DeAminases that act on RNA) in human hepatocellular carcinoma. <i>Gut</i> , 2014, 63, 832-843.	6.1	187
103	Editing liver tumours. <i>Gut</i> , 2014, 63, 709-710.	6.1	1
104	RNA Editome Imbalance in Hepatocellular Carcinoma. <i>Cancer Research</i> , 2014, 74, 1301-1306.	0.4	47
105	Hippocampus-specific deficiency in RNA editing of GluA2 in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2014, 35, 1785-1791.	1.5	94
106	Abnormal expression of an ADAR2 alternative splicing variant in gliomas downregulates adenosine-to-inosine RNA editing. <i>Acta Neurochirurgica</i> , 2014, 156, 1135-1142.	0.9	13
107	High-Resolution Genomic Analysis of Human Mitochondrial RNA Sequence Variation. <i>Science</i> , 2014, 344, 413-415.	6.0	90
108	The emerging role of RNA and DNA editing in cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1845, 308-316.	3.3	26
109	Involvement of Mediator complex in malignancy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1845, 66-83.	3.3	67
110	A biochemical landscape of A-to-I RNA editing in the human brain transcriptome. <i>Genome Research</i> , 2014, 24, 522-534.	2.4	121
111	Characterizing of functional human coding RNA editing from evolutionary, structural, and dynamic perspectives. <i>Proteins: Structure, Function and Bioinformatics</i> , 2014, 82, 3117-3131.	1.5	15
112	Human somatic cell mutagenesis creates genetically tractable sarcomas. <i>Nature Genetics</i> , 2014, 46, 964-972.	9.4	29
113	ADAR1 Is Involved in the Regulation of Reprogramming Human Fibroblasts to Induced Pluripotent Stem Cells. <i>Stem Cells and Development</i> , 2014, 23, 443-456.	1.1	14
114	Functional Impact of RNA editing and ADARs on regulation of gene expression: perspectives from deep sequencing studies. <i>Cell and Bioscience</i> , 2014, 4, 44.	2.1	22

#	ARTICLE	IF	CITATIONS
115	The RNA editing enzymes ADARs: mechanism of action and human disease. <i>Cell and Tissue Research</i> , 2014, 356, 527-532.	1.5	35
116	Conserved microRNA editing in mammalian evolution, development and disease. <i>Genome Biology</i> , 2014, 15, R83.	13.9	70
117	New Insights into the Biological Role of Mammalian ADARs; the RNA Editing Proteins. <i>Biomolecules</i> , 2015, 5, 2338-2362.	1.8	66
118	Exome sequencing of a colorectal cancer family reveals shared mutation pattern and predisposition circuitry along tumor pathways. <i>Frontiers in Genetics</i> , 2015, 6, 288.	1.1	11
120	PTBP1 induces ADAR1 p110 isoform expression through IRES-like dependent translation control and influences cell proliferation in gliomas. <i>Cellular and Molecular Life Sciences</i> , 2015, 72, 4383-4397.	2.4	32
121	RNA sequencing from human neutrophils reveals distinct transcriptional differences associated with chronic inflammatory states. <i>BMC Medical Genomics</i> , 2015, 8, 55.	0.7	61
122	Elevated RNA Editing Activity Is a Major Contributor to Transcriptomic Diversity in Tumors. <i>Cell Reports</i> , 2015, 13, 267-276.	2.9	262
123	Aberrant alternative splicing pattern of ADAR2 downregulates adenosine-to-inosine editing in glioma. <i>Oncology Reports</i> , 2015, 33, 2845-2852.	1.2	21
124	Recognition of duplex RNA by the deaminase domain of the RNA editing enzyme ADAR2. <i>Nucleic Acids Research</i> , 2015, 43, 1123-1132.	6.5	38
125	Monitoring the Spatiotemporal Activities of miRNAs in Small Animal Models Using Molecular Imaging Modalities. <i>International Journal of Molecular Sciences</i> , 2015, 16, 4947-4972.	1.8	15
126	RNA rewriting, recoding, and rewiring in human disease. <i>Trends in Molecular Medicine</i> , 2015, 21, 549-559.	3.5	60
127	Biochemical and Transcriptome-Wide Identification of A-to-I RNA Editing Sites by ICE-Seq. <i>Methods in Enzymology</i> , 2015, 560, 331-353.	0.4	3
128	Inconsistency and features of single nucleotide variants detected in whole exome sequencing versus transcriptome sequencing: A case study in lung cancer. <i>Methods</i> , 2015, 83, 118-127.	1.9	33
129	Case-control study of ADARB1 and ADARB2 gene variants in migraine. <i>Journal of Headache and Pain</i> , 2015, 16, 511.	2.5	6
130	Modulation of microRNA editing, expression and processing by ADAR2 deaminase in glioblastoma. <i>Genome Biology</i> , 2015, 16, 5.	3.8	125
131	Transcriptome-wide identification of adenosine-to-inosine editing using the ICE-seq method. <i>Nature Protocols</i> , 2015, 10, 715-732.	5.5	67
132	The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers. <i>Cancer Cell</i> , 2015, 28, 515-528.	7.7	426
133	Principles Governing A-to-I RNA Editing in the Breast Cancer Transcriptome. <i>Cell Reports</i> , 2015, 13, 277-289.	2.9	179

#	ARTICLE	IF	CITATIONS
134	Genome-wide identification of RNA editing in hepatocellular carcinoma. <i>Genomics</i> , 2015, 105, 76-82.	1.3	40
135	Aberrant overexpression of ADAR1 promotes gastric cancer progression by activating mTOR/p70S6K signaling. <i>Oncotarget</i> , 2016, 7, 86161-86173.	0.8	17
136	ADAR-Mediated RNA Editing Predicts Progression and Prognosis of Gastric Cancer. <i>Gastroenterology</i> , 2016, 151, 637-650.e10.	0.6	127
137	Altered RNA editing in 3' UTR perturbs microRNA-mediated regulation of oncogenes and tumor-suppressors. <i>Scientific Reports</i> , 2016, 6, 23226.	1.6	77
138	Copy number variation in archival melanoma biopsies versus benign melanocytic lesions. <i>Cancer Biomarkers</i> , 2016, 16, 575-597.	0.8	4
139	A novel IGH@ gene rearrangement associated with CDKN2A/B deletion in young adult B-cell acute lymphoblastic leukemia. <i>Oncology Letters</i> , 2016, 11, 2117-2122.	0.8	4
140	To edit or not to edit: regulation of ADAR editing specificity and efficiency. <i>Wiley Interdisciplinary Reviews RNA</i> , 2016, 7, 113-127.	3.2	67
141	Association between targeted somatic mutation (TSM) signatures and HGS-OvCa progression. <i>Cancer Medicine</i> , 2016, 5, 2629-2640.	1.3	18
142	Etiology and Pathogenesis of Hepatocellular Carcinoma: Epigenetic Mechanisms. , 2016, , 1-13.		0
143	Small RNA Modifications: Integral to Function and Disease. <i>Trends in Molecular Medicine</i> , 2016, 22, 1025-1034.	3.5	90
144	Controlling the Editor: The Many Roles of RNA-Binding Proteins in Regulating A-to-I RNA Editing. <i>Advances in Experimental Medicine and Biology</i> , 2016, 907, 189-213.	0.8	12
145	Complex regulation of ADAR-mediated RNA-editing across tissues. <i>BMC Genomics</i> , 2016, 17, 61.	1.2	69
146	Genetic Architectures of Quantitative Variation in RNA Editing Pathways. <i>Genetics</i> , 2016, 202, 787-798.	1.2	25
147	Reduced levels of protein recoding by A-to-I RNA editing in Alzheimer's disease. <i>Rna</i> , 2016, 22, 290-302.	1.6	122
148	Regulation of Antimicrobial Peptide Gene Expression by Vitamin D. , 2016, , 101-113.		1
149	RNA Editing Modulates Human Hepatic Aryl Hydrocarbon Receptor Expression by Creating MicroRNA Recognition Sequence. <i>Journal of Biological Chemistry</i> , 2016, 291, 894-903.	1.6	43
150	Synthesis of native-like crosslinked duplex RNA and study of its properties. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 2191-2199.	1.4	7
151	Construction of a guide-RNA for site-directed RNA mutagenesis utilising intracellular A-to-I RNA editing. <i>Scientific Reports</i> , 2017, 7, 41478.	1.6	83

#	ARTICLE	IF	CITATIONS
152	A-to-I RNA Editing Up-regulates Human Dihydrofolate Reductase in Breast Cancer. <i>Journal of Biological Chemistry</i> , 2017, 292, 4873-4884.	1.6	83
153	State of the art technologies to explore long non-coding RNAs in cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2017, 21, 3120-3140.	1.6	58
154	RNA editing of <i>SLC22A3</i> drives early tumor invasion and metastasis in familial esophageal cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E4631-E4640.	3.3	78
155	ADAR1-mediated 5' UTR editing and expression control of antiapoptosis genes fine-tunes cellular apoptosis response. <i>Cell Death and Disease</i> , 2017, 8, e2833-e2833.	2.7	37
156	Assessment of nucleosides as putative tumor biomarkers in prostate cancer screening by CE-UV. <i>Analytical and Bioanalytical Chemistry</i> , 2017, 409, 3289-3297.	1.9	14
157	Mechanisms and implications of ADAR-mediated RNA editing in cancer. <i>Cancer Letters</i> , 2017, 411, 27-34.	3.2	30
158	In cancer, A-to-I RNA editing can be the driver, the passenger, or the mechanic. <i>Drug Resistance Updates</i> , 2017, 32, 16-22.	6.5	17
159	Rare ADAR and RNASEH2B variants and a type I interferon signature in glioma and prostate carcinoma risk and tumorigenesis. <i>Acta Neuropathologica</i> , 2017, 134, 905-922.	3.9	12
160	Metabolomic and Lipidomic Profiling Identifies The Role of the RNA Editing Pathway in Endometrial Carcinogenesis. <i>Scientific Reports</i> , 2017, 7, 8803.	1.6	30
161	RNA editing is induced by type I interferon in esophageal squamous cell carcinoma. <i>Tumor Biology</i> , 2017, 39, 101042831770854.	0.8	10
162	RNA Editing in Pathogenesis of Cancer. <i>Cancer Research</i> , 2017, 77, 3733-3739.	0.4	60
163	Transposable Elements in Human Cancer: Causes and Consequences of Deregulation. <i>International Journal of Molecular Sciences</i> , 2017, 18, 974.	1.8	128
164	iRNA-AI: identifying the adenosine to inosine editing sites in RNA sequences. <i>Oncotarget</i> , 2017, 8, 4208-4217.	0.8	209
165	Elucidation of the genetic and epigenetic landscape alterations in RNA binding proteins in glioblastoma. <i>Oncotarget</i> , 2017, 8, 16650-16668.	0.8	36
166	Analysis of RNA Editing Sites from RNA-Seq Data Using GIREMI. <i>Methods in Molecular Biology</i> , 2018, 1751, 101-108.	0.4	7
167	Epigenetic and epitranscriptomic changes in colorectal cancer: Diagnostic, prognostic, and treatment implications. <i>Cancer Letters</i> , 2018, 419, 84-95.	3.2	52
168	Comprehensive Genomic Characterization of RNA-Binding Proteins across Human Cancers. <i>Cell Reports</i> , 2018, 22, 286-298.	2.9	166
169	Adenosine-to-Inosine RNA Editing in Health and Disease. <i>Antioxidants and Redox Signaling</i> , 2018, 29, 846-863.	2.5	34

#	ARTICLE	IF	CITATIONS
170	The Role of RNA Editing in Cancer Development and Metabolic Disorders. <i>Frontiers in Endocrinology</i> , 2018, 9, 762.	1.5	70
171	Enhanced AZIN1 RNA editing and overexpression of its regulatory enzyme ADAR1 are important prognostic biomarkers in gastric cancer. <i>Journal of Translational Medicine</i> , 2018, 16, 366.	1.8	48
172	CircNT5E Acts as a Sponge of miR-422a to Promote Glioblastoma Tumorigenesis. <i>Cancer Research</i> , 2018, 78, 4812-4825.	0.4	236
173	ADAR Mediated RNA Editing Modulates MicroRNA Targeting in Human Breast Cancer. <i>Processes</i> , 2018, 6, 42.	1.3	14
174	CLEC3B is downregulated and inhibits proliferation in clear cell renal cell carcinoma. <i>Oncology Reports</i> , 2018, 40, 2023-2035.	1.2	23
175	RNA editing of Filamin A pre-mRNA regulates vascular contraction and diastolic blood pressure. <i>EMBO Journal</i> , 2018, 37, .	3.5	86
176	RNA Editing Deficiency in Neurodegeneration. <i>Advances in Neurobiology</i> , 2018, 20, 63-83.	1.3	13
177	ADAR1 promotes the epithelial-to-mesenchymal transition and stem-like cell phenotype of oral cancer by facilitating oncogenic microRNA maturation. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 315.	3.5	35
178	Cancer therapeutic RNA-binding proteins as therapeutic targets for cancer. , 2019, 203, 107390.		125
179	Landscape of RNA editing reveals new insights into the dynamic gene regulation of spermatogenesis. <i>Cell Cycle</i> , 2019, 18, 3351-3364.	1.3	5
180	RNA editing in the forefront of epitranscriptomics and human health. <i>Journal of Translational Medicine</i> , 2019, 17, 319.	1.8	86
181	RNA binding candidates for human ADAR3 from substrates of a gain of function mutant expressed in neuronal cells. <i>Nucleic Acids Research</i> , 2019, 47, 10801-10814.	6.5	17
182	EPAI-NC: Enhanced prediction of adenosine to inosine RNA editing sites using nucleotide compositions. <i>Analytical Biochemistry</i> , 2019, 569, 16-21.	1.1	11
183	CREDO: Highly confident disease-relevant A-to-I RNA-editing discovery in breast cancer. <i>Scientific Reports</i> , 2019, 9, 5064.	1.6	3
184	Promising member of the short interspersed nuclear elements (Alu elements): mechanisms and clinical applications in human cancers. <i>Journal of Medical Genetics</i> , 2019, 56, 639-645.	1.5	5
185	Genome-wide identification of RNA editing in seven porcine tissues by matched DNA and RNA high-throughput sequencing. <i>Journal of Animal Science and Biotechnology</i> , 2019, 10, 24.	2.1	17
186	Dynamic inosinome profiles reveal novel patient stratification and gender-specific differences in glioblastoma. <i>Genome Biology</i> , 2019, 20, 33.	3.8	49
187	The adaptive potential of RNA editing-mediated miRNA-retargeting in cancer. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2019, 1862, 291-300.	0.9	15

#	ARTICLE	IF	CITATIONS
188	IL6R-STAT3-ADAR1 (P150) interplay promotes oncogenicity in multiple myeloma with 1q21 amplification. <i>Haematologica</i> , 2020, 105, 1391-1404.	1.7	34
189	RNA Modifications in Cancer: Functions, Mechanisms, and Therapeutic Implications. <i>Annual Review of Cancer Biology</i> , 2020, 4, 221-240.	2.3	60
190	De Novo A-to-I RNA Editing Discovery in lncRNA. <i>Cancers</i> , 2020, 12, 2959.	1.7	15
191	Fibroblast Growth Factor-14 Acts as Tumor Suppressor in Lung Adenocarcinomas. <i>Cells</i> , 2020, 9, 1755.	1.8	12
192	Stem cell programs in cancer initiation, progression, and therapy resistance. <i>Theranostics</i> , 2020, 10, 8721-8743.	4.6	208
193	DNA Methylation Distinguishes Head and Neck Cancer from Potentially Malignant Oral Lesions and Healthy Oral Mucosa. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6853.	1.8	10
194	RNA Editing Alters miRNA Function in Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2020, 12, 1159.	1.7	11
195	Quantifying RNA Editing in Deep Transcriptome Datasets. <i>Frontiers in Genetics</i> , 2020, 11, 194.	1.1	27
196	iMRM: a platform for simultaneously identifying multiple kinds of RNA modifications. <i>Bioinformatics</i> , 2020, 36, 3336-3342.	1.8	122
197	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal/Anal Task Forces whitepaper. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 757-770.	12.5	218
198	Suppression of adenosine-to-inosine (A-to-I) RNA editome by death associated protein 3 (DAP3) promotes cancer progression. <i>Science Advances</i> , 2020, 6, eaba5136.	4.7	29
199	Cis- and trans-regulations of pre-mRNA splicing by RNA editing enzymes influence cancer development. <i>Nature Communications</i> , 2020, 11, 799.	5.8	69
200	Dysregulations of Functional RNA Modifications in Cancer, Cancer Stemness and Cancer Therapeutics. <i>Theranostics</i> , 2020, 10, 3164-3189.	4.6	37
201	Deletion of Endonuclease V suppresses chemically induced hepatocellular carcinoma. <i>Nucleic Acids Research</i> , 2020, 48, 4463-4479.	6.5	9
202	AKT-Dependent Phosphorylation of ADAR1p110 and ADAR2 Represents a New and Important Link Between Cell Signaling and RNA Editing. <i>DNA and Cell Biology</i> , 2020, 39, 343-348.	0.9	6
203	The Emerging Roles of RNA Modifications in Glioblastoma. <i>Cancers</i> , 2020, 12, 736.	1.7	83
204	Epigenetic footprint enables molecular risk stratification of hepatoblastoma with clinical implications. <i>Journal of Hepatology</i> , 2020, 73, 328-341.	1.8	82
205	Systematic identification of A-to-I editing associated regulators from multiple human cancers. <i>Computers in Biology and Medicine</i> , 2020, 119, 103690.	3.9	1

#	ARTICLE	IF	CITATIONS
206	RNA editing contributes to epitranscriptome diversity in chronic lymphocytic leukemia. <i>Leukemia</i> , 2021, 35, 1053-1063.	3.3	17
207	RNA Editing in Neurological and Neurodegenerative Disorders. <i>Methods in Molecular Biology</i> , 2021, 2181, 309-330.	0.4	16
208	ADARs, RNA editing and more in hematological malignancies. <i>Leukemia</i> , 2021, 35, 346-359.	3.3	10
209	ADAR1 is a new target of METTL3 and plays a pro-oncogenic role in glioblastoma by an editing-independent mechanism. <i>Genome Biology</i> , 2021, 22, 51.	3.8	71
210	The effects of RNA editing in cancer tissue at different stages in carcinogenesis. <i>RNA Biology</i> , 2021, 18, 1-16.	1.5	15
211	â€œ3Câ€•Trial: An RNA Editing Signature to Guide Gastric Cancer Chemotherapy. <i>Cancer Research</i> , 2021, 81, 2788-2798.	0.4	9
212	The Emerging Impact of RNA Editing in Tumor Growth and Metastasis. <i>Annals of Military and Health Sciences Research</i> , 2021, 19, .	0.1	0
214	Inosine in Biology and Disease. <i>Genes</i> , 2021, 12, 600.	1.0	45
215	RNA A-to-I editing, environmental exposure, and human diseases. <i>Critical Reviews in Toxicology</i> , 2021, 51, 456-466.	1.9	6
216	Targeting RNA editing of antizyme inhibitor 1: A potential oligonucleotide-based antisense therapy for cancer. <i>Molecular Therapy</i> , 2021, 29, 3258-3273.	3.7	13
217	Identification of A-to-I RNA editing profiles and their clinical relevance in lung adenocarcinoma. <i>Science China Life Sciences</i> , 2022, 65, 19-32.	2.3	6
218	Identification and Analysis of RNA Editing Events in Ovarian Serous Cystadenoma Using RNA-seq Data. <i>Current Gene Therapy</i> , 2021, 21, 258-269.	0.9	4
219	Direct Immunodetection of Global Aâ€•toâ€•I RNA Editing Activity with a Chemiluminescent Bioassay. <i>Angewandte Chemie</i> , 2021, 133, 17146-17154.	1.6	1
220	Direct Immunodetection of Global Aâ€•toâ€•I RNA Editing Activity with a Chemiluminescent Bioassay. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 17009-17017.	7.2	10
221	Epitranscriptomics: A New Layer of microRNA Regulation in Cancer. <i>Cancers</i> , 2021, 13, 3372.	1.7	16
222	bCNN-Methylpred: Feature-Based Prediction of RNA Sequence Modification Using Branch Convolutional Neural Network. <i>Genes</i> , 2021, 12, 1155.	1.0	4
223	Epitranscriptomic Modifications Modulate Normal and Pathological Functions in CNS. <i>Translational Stroke Research</i> , 2022, 13, 1-11.	2.3	14
224	RNA Modifications and Epigenetics in Modulation of Lung Cancer and Pulmonary Diseases. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10592.	1.8	61

#	ARTICLE	IF	CITATIONS
225	RDDSVM: accurate prediction of A-to-I RNA editing sites from sequence using support vector machines. <i>Functional and Integrative Genomics</i> , 2021, 21, 633-643.	1.4	5
226	ADAR-mediated RNA editing of DNA:RNA hybrids is required for DNA double strand break repair. <i>Nature Communications</i> , 2021, 12, 5512.	5.8	30
228	Biochemical Identification of A-to-I RNA Editing Sites by the Inosine Chemical Erasing (ICE) Method. <i>Methods in Molecular Biology</i> , 2011, 718, 89-99.	0.4	22
229	Optic Pathway Gliomas. <i>Advances and Technical Standards in Neurosurgery</i> , 2015, 42, 123-146.	0.2	17
230	MicroRNAs in Epithelial Ovarian Cancer. , 2011, , 309-342.		2
231	To protect and modify double-stranded RNA – the critical roles of ADARs in development, immunity and oncogenesis. <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 2021, 56, 54-87.	2.3	28
232	Statistical inference of differential RNA-editing sites from RNA-sequencing data by hierarchical modeling. <i>Bioinformatics</i> , 2020, 36, 2796-2804.	1.8	14
233	Attenuated adenosine-to-inosine editing of microRNA-376a* promotes invasiveness of glioblastoma cells. <i>Journal of Clinical Investigation</i> , 2012, 122, 4059-4076.	3.9	175
234	MicroRNA-mediated loss of ADAR1 in metastatic melanoma promotes tumor growth. <i>Journal of Clinical Investigation</i> , 2013, 123, 2703-2718.	3.9	149
235	A mark of disease: how mRNA modifications shape genetic and acquired pathologies. <i>Rna</i> , 2021, 27, 367-389.	1.6	24
236	PRESa2i: incremental decision trees for prediction of Adenosine to Inosine RNA editing sites. <i>F1000Research</i> , 0, 9, 262.	0.8	6
237	Computational Detection and Functional Analysis of Human Tissue-Specific A-to-I RNA Editing. <i>PLoS ONE</i> , 2011, 6, e18129.	1.1	17
238	A-to-I RNA editing of BLCAP lost the inhibition to STAT3 activation in cervical cancer. <i>Oncotarget</i> , 2017, 8, 39417-39429.	0.8	39
239	Epigenome-wide association study in hepatocellular carcinoma: Identification of stochastic epigenetic mutations through an innovative statistical approach. <i>Oncotarget</i> , 2017, 8, 41890-41902.	0.8	47
240	Detection of canonical A-to-G editing events at 3' UTRs and microRNA target sites in human lungs using next-generation sequencing. <i>Oncotarget</i> , 2015, 6, 35726-35736.	0.8	15
241	ADAR, the carcinogenesis mechanisms of ADAR and related clinical applications. <i>Annals of Translational Medicine</i> , 2019, 7, 686-686.	0.7	13
242	Mediator kinase module and human tumorigenesis. <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 2015, 50, 393-426.	2.3	88
243	Differential expression of microRNAs in dorsal root ganglia after sciatic nerve injury. <i>Neural Regeneration Research</i> , 2014, 9, 1031.	1.6	10

#	ARTICLE	IF	CITATIONS
244	Identification of Diverse Adenosine-to-Inosine RNA Editing Subtypes in Colorectal Cancer. <i>Cancer Research and Treatment</i> , 2017, 49, 1077-1087.	1.3	22
245	Bioinformatics Strategies for Identifying Regions of Epigenetic Deregulation Associated with Aberrant Transcript Splicing and RNA-editing. , 2015, , .		1
246	Global RNA editome landscape discovers reduced RNA editing in glioma: loss of editing of gamma-amino butyric acid receptor alpha subunit 3 (GABRA3) favors glioma migration and invasion. <i>PeerJ</i> , 2020, 8, e9755.	0.9	13
247	Metabolomic Detection Between Pancreatic Cancer and Liver Metastasis Nude Mouse Models Constructed by Using the PANC1-KAI1/CD82 Cell Line. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110452.	0.8	2
248	Alu RNA and their roles in human disease states. <i>RNA Biology</i> , 2021, 18, 574-585.	1.5	11
249	Identification of RNA Editing Sites in Chimpanzee by Transcriptome-wide Sequencing Data*. <i>Progress in Biochemistry and Biophysics</i> , 2012, 39, 282-293.	0.3	0
250	Bioinformatics Approaches for the Identification and Annotation of RNA Editing Sites. <i>Journal of Genetic Medicine</i> , 2013, 10, 27-32.	0.1	0
252	Etiology and Pathogenesis of Hepatocellular Carcinoma: Epigenetic Mechanisms. , 2017, , 3029-3040.		0
254	Genomic Applications and Insights in Unravelling Cancer Signalling Pathways. , 2019, , 471-511.		0
257	Roles of retrotransposons in benign and malignant hematologic disease. <i>Cellscience</i> , 2009, 6, 121-145.	0.3	5
258	Genome-wide perturbations of Alu expression and Alu-associated post-transcriptional regulations distinguish oligodendroglioma from other gliomas. <i>Communications Biology</i> , 2022, 5, 62.	2.0	3
260	Aberrant Expression of ADARB1 Facilitates Temozolomide Chemoresistance and Immune Infiltration in Glioblastoma. <i>Frontiers in Pharmacology</i> , 2022, 13, 768743.	1.6	3
261	ADAR1-mediated RNA editing links ganglioside catabolism to glioblastoma stem cell maintenance. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	27
262	Nano-immunotherapeutic strategies for targeted RNA delivery: Emphasizing the role of monocyte/macrophages as nanovehicles to treat glioblastoma multiforme. <i>Journal of Drug Delivery Science and Technology</i> , 2022, 71, 103288.	1.4	5
263	Conservation of A-to-I RNA editing in bowhead whale and pig. <i>PLoS ONE</i> , 2021, 16, e0260081.	1.1	2
265	Interplay between A-to-I Editing and Splicing of RNA: A Potential Point of Application for Cancer Therapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5240.	1.8	9
266	Dynamic Network Construction for Identifying Early Warning Signals Based On a Data-Driven Approach: Early Diagnosis Biomarker Discovery for Gastric Cancer. <i>IEEE/ACM Transactions on Computational Biology and Bioinformatics</i> , 2023, 20, 923-931.	1.9	1
267	An investigation of the relationship between matriptase-2 protein expression and histopathological data in breast cancer. , 2022, 33, 201074.		0

#	ARTICLE	IF	CITATIONS
268	Noncoding RNAs as sensors of tumor microenvironmental stress. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	8
269	ADAR2 Protein Is Associated with Overall Survival in GBM Patients and Its Decrease Triggers the Anchorage-Independent Cell Growth Signature. <i>Biomolecules</i> , 2022, 12, 1142.	1.8	1
270	ADAR3 activates NF- κ B signaling and promotes glioblastoma cell resistance to temozolomide. <i>Scientific Reports</i> , 2022, 12, .	1.6	11
272	The allelic regulation of tumor suppressor ADARB2 in papillary thyroid carcinoma. <i>Endocrine-Related Cancer</i> , 2022, , .	1.6	1
273	Epigenetic Regulations in Autoimmunity and Cancer: from Basic Science to Translational Medicine. <i>European Journal of Immunology</i> , 2023, 53, .	1.6	3
274	The Interplay between RNA Editing Regulator ADAR1 and Immune Environment in Colorectal Cancer. <i>Journal of Oncology</i> , 2023, 2023, 1-13.	0.6	4
276	Understanding the Epitranscriptome for Avant-Garde Brain Tumour Diagnostics. <i>Cancers</i> , 2023, 15, 1232.	1.7	2
277	Regulation of posttranscriptional events by RNA-binding proteins. , 2023, , 93-108.		0
279	Clinical relevance of RNA editing profiles in lung adenocarcinoma. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	0
280	The emerging roles of epitranscriptomic marks in cancer. , 2023, , 129-141.		0
281	Deciphering glioma epitranscriptome: focus on RNA modifications. <i>Oncogene</i> , 2023, 42, 2197-2206.	2.6	3
283	Regulation and functions of non-m6A mRNA modifications. <i>Nature Reviews Molecular Cell Biology</i> , 2023, 24, 714-731.	16.1	25
288	Recent Advances in Adenosine-to-Inosine RNA Editing in Cancer. <i>Cancer Treatment and Research</i> , 2023, , 143-179.	0.2	0